



## **Corporate Press Release**

20<sup>th</sup> November 2012

### **Norgine Extends Partnership with PharmaSwiss SA, a division of Valeant Pharmaceutical International Inc. in Central and Eastern Europe**

Norgine, the leading European specialty pharmaceutical company, has today announced that it has appointed PharmaSwiss SA, a division of Valeant Pharmaceutical International Inc. as its partner for MOVICOL<sup>®</sup> in Central and Eastern Europe. MOVICOL is the leading brand in Europe for the treatment of constipation and this agreement further extends the successful working partnership between the two companies, as Valeant Europe already market MOVIPREP<sup>®</sup> in Central and Eastern Europe.

Commenting on the agreement, Paul Pay, VP of Corporate & Business Development commented: "We are delighted to extend our partnership with PharmaSwiss SA, a division of Valeant Pharmaceutical International Inc. and we look forward to working with them to bring MOVICOL - the largest laxative brand in value in Europe, to the Central and Eastern European market"

Valeant Europe added that: "After the successful launch of MOVIPREP in Central and Eastern Europe, we look forward to extending our partnership with Norgine to help make MOVICOL as successful in our territories, as it is in the countries of Western Europe."

**ENDS**

## **About Valeant**

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and nonprescription pharmaceutical products that make a meaningful difference in patients' lives. Valeant is focused on the dermatology and neurology therapeutic areas primarily in the United States, Canada, Mexico, Brazil, Central and Eastern Europe, Australia, South East Asia and South Africa.

In September 2010, Valeant Pharmaceuticals International and Biovail Corporation merged to become one company. This compelling combination is expected to create tremendous value for stockholders of both companies as the businesses benefit from cost savings, greater commercial reach and enhanced financial strength and flexibility. The new combined company also completed a name change to Valeant Pharmaceuticals International, Inc. and our shares now trade on both the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbol "VRX".

Based in Montreal, Quebec, Canada, Valeant employs approximately 7,500 people worldwide. Valeant Europe generates revenues in more than 20 countries in Central and Eastern Europe from branded generic pharmaceutical products, OTC products and from agency/in-licensing arrangements with other research-based pharmaceutical companies where we distribute and market branded, patented products under long-term, renewable contracts. In March 2011, Valeant acquired PharmaSwiss, a privately-owned branded generics and OTC pharmaceutical company with a broad product portfolio in seven therapeutic areas and operations in 19 countries throughout Central and Eastern Europe. In August 2011, we acquired Sanitas, a publicly-traded specialty pharmaceutical company based in Lithuania. [www.valeant.com](http://www.valeant.com)

## **About Norgine**

Norgine is an independent, successful European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2011, Norgine's net product sales were €246 million and the company employs over 1,000 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology and supportive care.

The Company currently markets a range of products in various markets in its key therapeutic areas e.g. MOVICOL<sup>®</sup> for the treatment of constipation and faecal impaction, MOVIPREP<sup>®</sup> a bowel cleansing preparation, KLEAN-PREP<sup>®</sup> for large bowel preparation prior to colonoscopy

or surgery, XIFAXAN®\* for the treatment of traveller's diarrhoea and ORAMORPH® for the treatment of moderate to severe pain associated with cancer.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France.

For more information: [www.norgine.com](http://www.norgine.com).

**Media contact**

Julie Hornby Winfield  
Global Corporate Communications Manager  
Phone: +44 1895 826600

\*XIFAXAN is a registered trademark of Alfa-Wasserman Hungary KFT, licensed to the Norgine group of companies.